Back to Directory
Insulin Glargine
Performance & EnduranceLong-acting basal insulin analog providing 24-hour coverage, marketed as Lantus, Basaglar, Toujeo.
Key Benefits
- ✓24-hour basal coverage
- ✓Once-daily dosing
- ✓Reduced hypoglycemia vs NPH
- ✓No pronounced peak
- ✓Improved glycemic control
Dosing Information
Dosage Range
Variable
Frequency
Once daily
Typical Duration
Lifelong
Detailed Protocol
Administered via subcutaneous injection once daily at same time each day. Basal insulin independent of meals. Dose titrated to fasting glucose. Prescription required.
About Insulin Glargine
Insulin glargine is a long-acting insulin analog modified to precipitate subcutaneously, providing steady 24-hour basal insulin coverage. First long-acting analog. Multiple formulations available (U-100, U-300).
Research Notes
FDA-approved in 2000 (Lantus). Revolutionized basal insulin therapy. Multiple versions (Basaglar, Toujeo). Standard basal insulin option. Biosimilars available.
Potential Side Effects
- •Hypoglycemia
- •Weight gain
- •Injection site reactions
- •Lipodystrophy
Always consult with a healthcare professional before starting any peptide therapy.